Earnings Releases·Nov 4, 2026, 4:10 PM ET

ADMA Biologics — Third Quarter 2026 Earnings Summary

Q3 2026 total revenue rose 5% YoY to $141.1 million, driven by a 31% YoY increase in ASCENIV revenue to $124.7 million, while BIVIGAM revenue declined 35.2% YoY to $15.4 million; GAAP net income increased 37% YoY to $49.9 million and gross margin expanded 1,450 basis points YoY to 71%.
The company raised full-year 2026 guidance, now projecting at least $180 million in Adjusted Net Income and at least $275 million in Adjusted EBITDA, while reiterating total revenue guidance of at least $530 million.
SG-001 development advanced following constructive FDA feedback on the pre-IND package, with the company on track to complete its $200 million+ 2026 share repurchase target after buying 2.7 million shares in Q3.
Balance sheet changes include a cash and cash equivalents increase to $124.6 million and total debt rising to $195.9 million as of September 30, 2026, compared to $72.1 million at year-end 2025.